Identification

Name
Pantoprazole
Accession Number
DB00213  (APRD00073)
Type
Small Molecule
Groups
Approved
Description

Pantoprazole is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Structure
Thumb
Synonyms
  • Pantoprazol
  • Pantoprazolum
Product Ingredients
IngredientUNIICASInChI Key
Pantoprazole magnesium1AL13B11R4199387-73-0RDRUTBCDIVCMMX-UHFFFAOYSA-N
Pantoprazole magnesium hemipentahydrateNot AvailableNot AvailableNot applicable
Pantoprazole sodiumS9363155XL138786-67-1YNWDKZIIWCEDEE-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-pantoprazoleTablet, delayed release20 mgOralAbbottNot applicableNot applicableCanada
Abbott-pantoprazoleTablet, delayed release40 mgOralAbbott2014-03-172015-12-31Canada
Act PantoprazoleTablet, delayed release40 mgOralActavis Pharma Company2008-06-04Not applicableCanada
Auro-pantoprazoleTablet, delayed release40 mgOralAuro Pharma Inc2016-02-06Not applicableCanada
Ava-pantoprazoleTablet, delayed release20 mgOralAvanstra Inc2011-09-192014-08-21Canada
Ava-pantoprazoleTablet, delayed release40 mgOralAvanstra Inc2011-09-192014-08-21Canada
Bio-pantoprazoleTablet, delayed release40 mgOralBiomed Pharma2016-11-24Not applicableCanada
Controloc ControlTablet, delayed release20 mgOralTakeda2009-06-12Not applicableEu
Controloc ControlTablet, delayed release20 mgOralTakeda2009-06-12Not applicableEu
Controloc ControlTablet, delayed release20 mgOralTakeda2009-06-12Not applicableEu
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-pantoprazoleTablet, delayed release40 mgOralApotex Corporation2008-03-05Not applicableCanada
Apo-pantoprazoleTablet, delayed release20 mgOralApotex Corporation2008-03-05Not applicableCanada
PantoprazoleTablet, delayed release40 mg/1OralLegacy Pharmaceutical Packaging2011-01-192017-07-19Us
PantoprazoleTablet, delayed release40 mg/1OralDr Reddy's Laboratories2011-01-19Not applicableUs
PantoprazoleTablet, delayed release40 mg/1OralCardinal Health2011-01-19Not applicableUs
PantoprazoleTablet, delayed release40 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
PantoprazoleTablet, delayed release20 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
PantoprazoleTablet, delayed release20 mg/1OralDr Reddy's Laboratories2011-01-19Not applicableUs
PantoprazoleTablet, delayed release40 mg/1OralMajor2011-01-19Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralNucare Pharmaceuticals, Inc.2011-01-20Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Pantoprazole SodiumTablet, delayed release20 mg/1OralSt. Marys Medical Park Pharmacy2011-01-20Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralRemedy Repack2017-11-20Not applicableUs
International/Other Brands
Pantozol
Categories
UNII
D8TST4O562
CAS number
102625-70-7
Weight
Average: 383.37
Monoisotopic: 383.075133083
Chemical Formula
C16H15F2N3O4S
InChI Key
IQPSEEYGBUAQFF-UHFFFAOYSA-N
InChI
InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)
IUPAC Name
6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazole
SMILES
COC1=C(OC)C(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=NC=C1

Pharmacology

Indication

Short-term (up to 16 weeks) treatment of erosive esophagitis.

Structured Indications
Pharmacodynamics

Pantoprazole is a substituted benzimidazole indicated for the short-term treatment (up to 16 weeks) in the healing and symptomatic relief of erosive esophagitis. Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production.

Mechanism of action

Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production by forming a covalent bond to two sites of the (H+,K+ )- ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect is dose- related and leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus.

TargetActionsOrganism
APotassium-transporting ATPase alpha chain 1
inhibitor
Human
Absorption

Pantoprazole is well absorbed. It undergoes little first-pass metabolism resulting in an absolute bioavailability of approximately 77%.

Volume of distribution
  • 11.0 to 23.6 L
Protein binding

98%

Metabolism

Pantoprazole is extensively metabolized in the liver through the cytochrome P450 (CYP) system. The main metabolic pathway is demethylation, by CYP2C19, with subsequent sulfation; other metabolic pathways include oxidation by CYP3A4. There is no evidence that any of the pantoprazole metabolites have significant pharmacologic activity.

Route of elimination

After administration of a single intravenous dose of 14C-labeled pantoprazole to healthy, normal metabolizer subjects, approximately 71% of the dose was excreted in the urine with 18% excreted in the feces through biliary excretion.

Half life

1 hour

Clearance
  • 7.6-14.0 L/h
Toxicity

Single intravenous doses of pantoprazole at 378, 230, and 266 mg/kg (38, 46, and 177 times the recommended human dose based on body surface area) were lethal to mice, rats and dogs, respectively. The symptoms of toxicity included hypoactivity, ataxia, hunched sitting, limb-splay, lateral position, segregation, absence of ear reflex, and tremor. There is limited experience regarding cases of human overdosage, and treatment should be symptomatic and supportive.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Pantoprazole Action PathwayDrug action
Pantoprazole Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2C19CYP2C19*2ANot Available681G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*2BNot Available681G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*3Not Available636G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*4Not Available1A>GEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*5Not Available1297C>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*6Not Available395G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*7Not Available19294T>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*22Not Available557G>C / 991A>GEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*24Not Available99C>T / 991A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*35Not Available12662A>GEffect InferredPoor drug metabolizer.Details

Interactions

Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Pantoprazole can be increased when it is combined with Abiraterone.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Pantoprazole.Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Pantoprazole.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Pantoprazole.Approved
Alendronic acidThe therapeutic efficacy of Alendronic acid can be decreased when used in combination with Pantoprazole.Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Pantoprazole.Approved, Investigational
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Pantoprazole.Approved, Investigational
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Pantoprazole.Approved, Withdrawn
AmiodaroneThe metabolism of Pantoprazole can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Pantoprazole.Approved
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Pantoprazole.Approved, Vet Approved
AmphetaminePantoprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Illicit
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Pantoprazole.Approved
ApixabanThe metabolism of Apixaban can be decreased when combined with Pantoprazole.Approved
AprepitantThe serum concentration of Pantoprazole can be increased when it is combined with Aprepitant.Approved, Investigational
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Pantoprazole.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Pantoprazole.Approved, Investigational
ArmodafinilThe metabolism of Pantoprazole can be decreased when combined with Armodafinil.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Pantoprazole.Approved
AtazanavirPantoprazole can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtomoxetineThe metabolism of Pantoprazole can be decreased when combined with Atomoxetine.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Pantoprazole.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Pantoprazole.Approved
AzithromycinThe metabolism of Pantoprazole can be decreased when combined with Azithromycin.Approved
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Pantoprazole.Approved
BoceprevirThe metabolism of Pantoprazole can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Pantoprazole can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Pantoprazole can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Pantoprazole.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Pantoprazole.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Pantoprazole.Approved, Investigational
BromazepamThe metabolism of Bromazepam can be decreased when combined with Pantoprazole.Approved, Illicit
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Pantoprazole.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Pantoprazole.Approved, Investigational
CaffeineThe metabolism of Pantoprazole can be decreased when combined with Caffeine.Approved
CarbamazepineThe metabolism of Pantoprazole can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Pantoprazole.Approved
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Pantoprazole.Approved
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Pantoprazole.Approved
CeritinibThe serum concentration of Pantoprazole can be increased when it is combined with Ceritinib.Approved
ChloramphenicolThe metabolism of Pantoprazole can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Pantoprazole.Approved
CholecalciferolThe metabolism of Pantoprazole can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Pantoprazole.Approved
CimetidineThe metabolism of Pantoprazole can be decreased when combined with Cimetidine.Approved
CisaprideThe metabolism of Cisapride can be decreased when combined with Pantoprazole.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Pantoprazole.Approved
ClarithromycinThe metabolism of Pantoprazole can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Pantoprazole can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Pantoprazole.Approved, Illicit
Clodronic AcidThe therapeutic efficacy of Clodronic Acid can be decreased when used in combination with Pantoprazole.Approved, Investigational, Vet Approved
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Pantoprazole.Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Pantoprazole.Approved, Vet Approved
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Pantoprazole resulting in a loss in efficacy.Approved, Nutraceutical
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Pantoprazole.Approved, Illicit
ClotrimazoleThe metabolism of Pantoprazole can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Pantoprazole.Approved
CobicistatThe metabolism of Pantoprazole can be decreased when combined with Cobicistat.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Pantoprazole.Approved
ConivaptanThe serum concentration of Pantoprazole can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Pantoprazole can be decreased when combined with Crizotinib.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Pantoprazole.Approved, Investigational
CyclosporineThe metabolism of Pantoprazole can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Pantoprazole can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Pantoprazole.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Pantoprazole.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Pantoprazole.Approved
DapsoneThe metabolism of Dapsone can be decreased when combined with Pantoprazole.Approved, Investigational
DarunavirThe metabolism of Pantoprazole can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Pantoprazole can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Pantoprazole can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Pantoprazole.Approved
DesipramineThe metabolism of Desipramine can be decreased when combined with Pantoprazole.Approved
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Pantoprazole.Approved
DexmethylphenidatePantoprazole can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
DextroamphetaminePantoprazole can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Pantoprazole.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Pantoprazole.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Pantoprazole.Approved, Vet Approved
DihydroergotamineThe metabolism of Pantoprazole can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Pantoprazole can be decreased when combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Pantoprazole.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Pantoprazole.Approved
DosulepinThe metabolism of Pantoprazole can be decreased when combined with Dosulepin.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Pantoprazole.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Pantoprazole.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Pantoprazole.Approved, Investigational
DoxycyclineThe metabolism of Pantoprazole can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe metabolism of Dronabinol can be decreased when combined with Pantoprazole.Approved, Illicit
DronedaroneThe metabolism of Pantoprazole can be decreased when combined with Dronedarone.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Pantoprazole.Approved
EfavirenzThe metabolism of Pantoprazole can be decreased when combined with Efavirenz.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Pantoprazole.Approved, Investigational
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Pantoprazole.Approved
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Pantoprazole.Approved, Investigational
EnzalutamideThe serum concentration of Pantoprazole can be decreased when it is combined with Enzalutamide.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Pantoprazole.Approved, Investigational
ErythromycinThe metabolism of Pantoprazole can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Pantoprazole.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Pantoprazole can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Pantoprazole.Approved, Investigational
EstradiolThe metabolism of Estradiol can be decreased when combined with Pantoprazole.Approved, Investigational, Vet Approved
Etidronic acidThe therapeutic efficacy of Etidronic acid can be decreased when used in combination with Pantoprazole.Approved
EtizolamThe metabolism of Etizolam can be decreased when combined with Pantoprazole.Approved
EtravirineThe metabolism of Etravirine can be decreased when combined with Pantoprazole.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Pantoprazole.Approved
FamotidineThe metabolism of Famotidine can be decreased when combined with Pantoprazole.Approved
Ferric CarboxymaltosePantoprazole can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitratePantoprazole can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Ferric pyrophosphatePantoprazole can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluconazoleThe serum concentration of Pantoprazole can be increased when it is combined with Fluconazole.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Pantoprazole.Approved, Illicit
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Pantoprazole.Approved, Vet Approved
FlutamideThe metabolism of Flutamide can be decreased when combined with Pantoprazole.Approved
FluvoxamineThe metabolism of Pantoprazole can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Pantoprazole.Approved, Investigational
FosamprenavirThe metabolism of Pantoprazole can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Pantoprazole can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Pantoprazole can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Pantoprazole can be increased when it is combined with Fusidic Acid.Approved
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Pantoprazole.Approved, Investigational
GemfibrozilThe metabolism of Pantoprazole can be decreased when combined with Gemfibrozil.Approved
GliclazideThe metabolism of Gliclazide can be decreased when combined with Pantoprazole.Approved
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Pantoprazole.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Pantoprazole.Approved
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Pantoprazole.Approved, Investigational
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Pantoprazole.Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Pantoprazole.Approved
IbandronateThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Pantoprazole.Approved, Investigational
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Pantoprazole.Approved
IdelalisibThe serum concentration of Pantoprazole can be increased when it is combined with Idelalisib.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Pantoprazole.Approved
ImatinibThe metabolism of Pantoprazole can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Imipramine can be decreased when combined with Pantoprazole.Approved
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Pantoprazole.Approved
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Pantoprazole.Approved, Investigational
IronPantoprazole can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranPantoprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharatePantoprazole can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsavuconazoniumThe metabolism of Pantoprazole can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Pantoprazole can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Pantoprazole can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Pantoprazole.Approved, Investigational
IvacaftorThe serum concentration of Pantoprazole can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Pantoprazole.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Pantoprazole.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Pantoprazole.Approved, Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Pantoprazole.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Pantoprazole.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Pantoprazole.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Pantoprazole.Approved
LidocaineThe metabolism of Pantoprazole can be decreased when combined with Lidocaine.Approved, Vet Approved
LobeglitazoneThe metabolism of Pantoprazole can be decreased when combined with Lobeglitazone.Approved, Investigational
LopinavirThe metabolism of Pantoprazole can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Pantoprazole.Approved
LovastatinThe metabolism of Pantoprazole can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Pantoprazole can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Pantoprazole can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Pantoprazole.Approved, Investigational
MacitentanThe metabolism of Macitentan can be decreased when combined with Pantoprazole.Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Pantoprazole.Approved, Nutraceutical, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Pantoprazole.Investigational, Withdrawn
MeprobamateThe metabolism of Meprobamate can be decreased when combined with Pantoprazole.Approved, Illicit
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Pantoprazole.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Pantoprazole.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Pantoprazole.Approved
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Pantoprazole.Approved
MethylphenidatePantoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Pantoprazole.Approved
MetoprololThe metabolism of Metoprolol can be decreased when combined with Pantoprazole.Approved, Investigational
MexiletineThe metabolism of Pantoprazole can be decreased when combined with Mexiletine.Approved
MidostaurinThe metabolism of Pantoprazole can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Pantoprazole can be increased when it is combined with Mifepristone.Approved, Investigational
MitotaneThe serum concentration of Pantoprazole can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Pantoprazole.Approved
ModafinilThe metabolism of Pantoprazole can be decreased when combined with Modafinil.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Pantoprazole.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Pantoprazole.Approved
NefazodoneThe metabolism of Pantoprazole can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Pantoprazole resulting in a loss in efficacy.Approved
NetupitantThe serum concentration of Pantoprazole can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Pantoprazole can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Pantoprazole can be decreased when combined with Nicardipine.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Pantoprazole.Approved
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Pantoprazole.Approved, Investigational
NilutamideThe metabolism of Nilutamide can be decreased when combined with Pantoprazole.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Pantoprazole.Approved
OlaparibThe metabolism of Pantoprazole can be decreased when combined with Olaparib.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Pantoprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Pantoprazole can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Pantoprazole.Approved
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Pantoprazole.Approved
PalbociclibThe serum concentration of Pantoprazole can be increased when it is combined with Palbociclib.Approved
PamidronateThe therapeutic efficacy of Pamidronate can be decreased when used in combination with Pantoprazole.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Pantoprazole.Approved
Peginterferon alfa-2bThe serum concentration of Pantoprazole can be increased when it is combined with Peginterferon alfa-2b.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Pantoprazole.Approved
PentobarbitalThe metabolism of Pantoprazole can be increased when combined with Pentobarbital.Approved, Vet Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Pantoprazole.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Pantoprazole.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Pantoprazole.Withdrawn
PhenobarbitalThe metabolism of Pantoprazole can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Pantoprazole can be increased when combined with Phenytoin.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Pantoprazole.Approved, Investigational
PodofiloxThe metabolism of Podofilox can be decreased when combined with Pantoprazole.Approved
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Pantoprazole.Approved, Investigational, Vet Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Pantoprazole.Approved
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Pantoprazole.Approved, Vet Approved
PrimidoneThe metabolism of Pantoprazole can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Pantoprazole.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Pantoprazole.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Pantoprazole.Approved, Vet Approved
PropofolThe metabolism of Propofol can be decreased when combined with Pantoprazole.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Pantoprazole.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Pantoprazole.Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Pantoprazole.Approved, Illicit
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Pantoprazole.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Pantoprazole.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Pantoprazole.Approved, Investigational
RaltegravirThe serum concentration of Raltegravir can be increased when it is combined with Pantoprazole.Approved
RamelteonThe metabolism of Ramelteon can be decreased when combined with Pantoprazole.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Pantoprazole.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Pantoprazole.Approved, Investigational
RifabutinThe metabolism of Pantoprazole can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Pantoprazole can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Pantoprazole can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Pantoprazole.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Pantoprazole.Approved
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Pantoprazole.Approved
RisedronateThe therapeutic efficacy of Risedronate can be decreased when used in combination with Pantoprazole.Approved, Investigational
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Pantoprazole.Approved, Investigational
RopiniroleThe metabolism of Pantoprazole can be decreased when combined with Ropinirole.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Pantoprazole.Approved
RupatadineThe metabolism of Rupatadine can be decreased when combined with Pantoprazole.Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Pantoprazole.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Pantoprazole.Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Pantoprazole.Approved, Investigational, Vet Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Pantoprazole.Approved
SertralineThe metabolism of Sertraline can be decreased when combined with Pantoprazole.Approved
SildenafilThe metabolism of Pantoprazole can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Pantoprazole.Approved
SiltuximabThe serum concentration of Pantoprazole can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Pantoprazole can be increased when it is combined with Simeprevir.Approved
St. John's WortThe serum concentration of Pantoprazole can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Pantoprazole can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Pantoprazole can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Pantoprazole.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Pantoprazole.Approved
TapentadolThe metabolism of Tapentadol can be decreased when combined with Pantoprazole.Approved
Technetium Tc-99m etidronateThe therapeutic efficacy of Technetium Tc-99m etidronate can be decreased when used in combination with Pantoprazole.Approved
Technetium Tc-99m medronateThe therapeutic efficacy of Technetium Tc-99m medronate can be decreased when used in combination with Pantoprazole.Approved
TelaprevirThe metabolism of Pantoprazole can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Pantoprazole can be decreased when combined with Telithromycin.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Pantoprazole.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Pantoprazole.Approved
Tenofovir disoproxilThe metabolism of Pantoprazole can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Pantoprazole.Approved, Investigational, Vet Approved
TeriflunomideThe serum concentration of Pantoprazole can be decreased when it is combined with Teriflunomide.Approved
TestosteroneThe metabolism of Testosterone can be decreased when combined with Pantoprazole.Approved, Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Pantoprazole.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Pantoprazole can be decreased when combined with Theophylline.Approved
ThioridazineThe metabolism of Thioridazine can be decreased when combined with Pantoprazole.Approved, Withdrawn
TiclopidineThe metabolism of Pantoprazole can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe therapeutic efficacy of Tiludronic acid can be decreased when used in combination with Pantoprazole.Approved, Investigational, Vet Approved
TimololThe metabolism of Timolol can be decreased when combined with Pantoprazole.Approved
TipranavirThe serum concentration of Pantoprazole can be decreased when it is combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Pantoprazole can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Pantoprazole.Approved, Investigational
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Pantoprazole.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Pantoprazole.Approved, Investigational
TopiramateThe metabolism of Pantoprazole can be decreased when combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Pantoprazole.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Pantoprazole.Approved, Investigational
TranylcypromineThe metabolism of Pantoprazole can be decreased when combined with Tranylcypromine.Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Pantoprazole.Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Pantoprazole.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Pantoprazole.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Pantoprazole.Approved, Investigational
VenlafaxineThe metabolism of Pantoprazole can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Pantoprazole can be decreased when combined with Verapamil.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Pantoprazole.Approved, Investigational
VoriconazoleThe serum concentration of Pantoprazole can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Pantoprazole.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Pantoprazole.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Pantoprazole.Approved
ZiprasidoneThe metabolism of Pantoprazole can be decreased when combined with Ziprasidone.Approved
Zoledronic acidThe therapeutic efficacy of Zoledronic acid can be decreased when used in combination with Pantoprazole.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Pantoprazole.Approved
ZucapsaicinThe metabolism of Pantoprazole can be decreased when combined with Zucapsaicin.Approved
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

Rudolf Linder, "Freeze-dried pantoprazole preparation and pantoprazole injection." U.S. Patent US20030003058, issued January 02, 2003.

US20030003058
General References
Not Available
External Links
Human Metabolome Database
HMDB05017
KEGG Drug
D05353
KEGG Compound
C11806
PubChem Compound
4679
PubChem Substance
46504622
ChemSpider
4517
BindingDB
50241342
ChEBI
7915
ChEMBL
CHEMBL1502
Therapeutic Targets Database
DAP000724
PharmGKB
PA450774
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Pantoprazole
ATC Codes
A02BC02 — PantoprazoleA02BD11 — Pantoprazole, amoxicillin, clarithromycin and metronidazoleA02BD04 — Pantoprazole, amoxicillin and clarithromycin
AHFS Codes
  • 56:28.36 — Proton-pump Inhibitors
FDA label
Download (183 KB)
MSDS
Download (58.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableDrug Interactions1
1CompletedNot AvailableHealthy Volunteers1
1CompletedBasic ScienceBacterial Infections1
1CompletedBasic ScienceDrug Interaction Potentiation1
1CompletedBasic ScienceDrug Interactions / Pharmacodynamics / Pharmacokinetics1
1CompletedBasic ScienceGastroesophageal Reflux Disease1
1CompletedBasic ScienceHealthy Volunteers2
1CompletedTreatmentAcute Coronary Syndromes (ACS)1
1CompletedTreatmentAdvanced Solid Tumours1
1CompletedTreatmentDisseminated Sclerosis1
1CompletedTreatmentFasting1
1CompletedTreatmentFed1
1CompletedTreatmentHealthy Volunteers12
1CompletedTreatmentReflux, Gastroesophageal1
1Unknown StatusBasic ScienceBMI >30 kg/m2 / GERD1
1Unknown StatusTreatmentHealthy Male Subjects1
1WithdrawnTreatmentInvasive Aspergillosis1
2Active Not RecruitingSupportive CareNephrotoxicity / Ototoxicity / Sarcoma, Osteogenic1
2Active Not RecruitingTreatmentProstate Cancer1
2CompletedPreventionPeptic ulcer haemorrhage1
2CompletedTreatmentAcute Cerebrovascular Accidents / Edema of the cerebrum1
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
2CompletedTreatmentGastrinoma / Zollinger-Ellison Syndrome1
2, 3CompletedTreatmentGastroesophageal Reflux Disease1
2, 3CompletedTreatmentType 2 Diabetes Mellitus1
2, 3RecruitingTreatmentAcute Exacerbation of Psychosis / Psychosis / Schizophrenic Disorders1
3Active Not RecruitingPreventionPrevention & Control1
3CompletedPreventionPeptic ulcer haemorrhage1
3CompletedPreventionStress Ulcer Prophylaxis1
3CompletedTreatmentGERD2
3CompletedTreatmentGastroesophageal Reflux Disease (GERD)1
3CompletedTreatmentGastroesophageal Reflux Disease (GERD) / Peptic Ulcers1
3CompletedTreatmentPeptic Ulcers1
3CompletedTreatmentPeptic Ulcers / Upper Gastrointestinal Hemorrhage1
3CompletedTreatmentReflux, Gastroesophageal6
3RecruitingTreatmentAcute and Chronic Inflammation / Indigestion1
3RecruitingTreatmentHemorrhage, Gastrointestinal1
3RecruitingTreatmentLaryngopharyngeal Reflux Disease1
3TerminatedTreatmentEsophageal Metaplasia1
3Unknown StatusTreatmentChronic Use of Acid Suppressive Medication / GERD / GORD / Peptic Ulcers / Reflux1
3Unknown StatusTreatmentDiabetes Mellitus (DM)1
3Unknown StatusTreatmentGastroesophageal Reflux Disease (GERD)1
3Unknown StatusTreatmentPeptic Ulcers1
3WithdrawnTreatmentCongestive Heart Failure (CHF)1
3WithdrawnTreatmentGastric pH Control1
3WithdrawnTreatmentGastroesophageal Reflux Disease1
4Active Not RecruitingPreventionGastrointestinal Bleedings / Stress Ulcers1
4CompletedNot AvailableHealthy Volunteers1
4CompletedDiagnosticBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
4CompletedPreventionNonvalvular Atrial Fibrillation1
4CompletedPreventionPeptic Ulcer/Erosions1
4CompletedPreventionPeptic ulcer haemorrhage1
4CompletedTreatmentAcid Reflux Disease / Obstructive Sleep Apnea (OSA)1
4CompletedTreatmentAcid Regurgitation / Heartburn / Nausea / Upper Abdominal Pain1
4CompletedTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)2
4CompletedTreatmentBioavailability / Concomitant Medication After Renal Transplantation / Drug Interactions / Immunosuppressive Medication After Renal Transplantation1
4CompletedTreatmentEmergency / Indigestion / Pain1
4CompletedTreatmentEsophagitis1
4CompletedTreatmentGERD / GORD / Reflux, Gastroesophageal1
4CompletedTreatmentGastroesophageal Reflux Disease3
4CompletedTreatmentHaemorrhage / Varices, Esophageal1
4CompletedTreatmentHelicobacter Infection1
4CompletedTreatmentIndigestion1
4CompletedTreatmentPeptic ulcer haemorrhage1
4CompletedTreatmentReflux, Gastroesophageal2
4CompletedTreatmentVasoconstrictor Choice on Acute Variceal Bleeding1
4Enrolling by InvitationNot AvailablePsychotic Disorder NOS / Reflux, Gastroesophageal1
4Not Yet RecruitingPreventionGastric Ulcer Induced by Antiplatelet Agent / Proton Pump Inhibitor / Ulcer of the Gastrointestinal Tract1
4Not Yet RecruitingTreatmentPostoperative pain1
4RecruitingOtherAcute Kidney Injury (AKI) / Critical Illness / End-Stage Renal Disease (ESRD) / Proton Pump Inhibitor / Renal Replacement Therapies1
4RecruitingTreatmentGastroesophageal Reflux Disease / Presumptive or Proven Gastroesophageal Reflux Disease (GERD)1
4RecruitingTreatmentNSAID-induced Gastropathy1
4RecruitingTreatmentRib Fractures / Wounds and Injuries1
4TerminatedTreatmentFunctional Dyspepsia1
4TerminatedTreatmentGastroesophageal Reflux Disease / Non-erosive Reflux Disease (NERD)1
4Unknown StatusPreventionAcute Coronary Syndromes (ACS)1
4Unknown StatusScreening30 Healthy People1
4Unknown StatusTreatmentCoronary Artery Disease1
4Unknown StatusTreatmentEsophageal Variceal Rebleeding1
4Unknown StatusTreatmentNonulcer Dyspepsia1
4WithdrawnTreatmentCoronary Artery Disease1
4WithdrawnTreatmentCoronary artery thrombosis / Positive Helicobacter Pylori Serology / Supra-aortic Artery Thrombosis1
4WithdrawnTreatmentEustachian Tube Dysfunction / Laryngopharyngeal Reflux1
4WithdrawnTreatmentPeptic Ulcers1
Not AvailableCompletedNot AvailableCommunity Acquired Pneumonia (CAP) / Gastroesophageal Reflux Disease (GERD)1
Not AvailableCompletedNot AvailableErosive Gastroesophageal Reflux Disease / Non-erosive Reflux Disease (NERD)1
Not AvailableCompletedNot AvailableGastroesophageal Reflux Disease2
Not AvailableCompletedNot AvailableGastroesophageal Reflux Disease / Non-erosive Reflux Disease (NERD) / Sleep disorders and disturbances1
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedNot AvailableHelicobacter Infections1
Not AvailableCompletedBasic ScienceHealthy Volunteers1
Not AvailableCompletedDiagnosticGERD1
Not AvailableCompletedSupportive CareAntiplatelet Effect1
Not AvailableCompletedTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)2
Not AvailableCompletedTreatmentCardiovascular Disease (CVD) / Cerebrovascular Disorders1
Not AvailableCompletedTreatmentGastric Ulcer (GU)1
Not AvailableCompletedTreatmentGastrointestinal Diseases / Indigestion1
Not AvailableCompletedTreatmentKnee Osteoarthritis (Knee OA)2
Not AvailableRecruitingDiagnosticNon-erosive Reflux Disease (NERD) / Reflux, Gastroesophageal1
Not AvailableRecruitingPreventionPeptic Ulcers1
Not AvailableRecruitingTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)2
Not AvailableRecruitingTreatmentElbow Trauma Requiring Operative Management1
Not AvailableTerminatedTreatmentNeoplasms Metastasis / Spinal Cord Compression1
Not AvailableTerminatedTreatmentUpper Gastrointestinal Bleed1
Not AvailableUnknown StatusPreventionDelayed Bleeding1
Not AvailableUnknown StatusTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
Not AvailableUnknown StatusTreatmentEndoscopy / Haemorrhage / Peptic Ulcers / Proton Pump Inhibitors1
Not AvailableUnknown StatusTreatmentHemochromatosis1

Pharmacoeconomics

Manufacturers
  • Wyeth pharmaceuticals inc
  • Kudco ireland ltd
  • Sun pharma global inc
  • Teva pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
Tablet, delayed releaseOral20 mg
Tablet, delayed releaseOral40 mg
Injection, powder, for solutionIntravenous40 mg/1
Injection, powder, lyophilized, for solutionIntravenous40 mg/1
TabletOral40 mg/1
Tablet, delayed releaseOral20 mg/1
Tablet, delayed releaseOral40 mg/1
Powder, for solutionIntravenous40 mg
Granule, delayed releaseOral40 mg/1
Injection, powder, for solutionIntravenous40 mg/10mL
Prices
Unit descriptionCostUnit
Protonix iv 40 mg vial14.4USD vial
Protonix 40 mg tablet dr8.91USD tablet
Protonix 20 mg tablet5.43USD tab
Protonix 40 mg Enteric Coated Tabs5.43USD tab
Protonix dr 20 mg tablet5.22USD tablet
Protonix dr 40 mg tablet5.22USD tablet
Pantoprazole Sodium 20 mg Enteric Coated Tabs4.26USD tab
Pantoprazole Sodium 40 mg Enteric Coated Tabs4.26USD tab
Pantoprazole sod dr 20 mg tablet3.93USD tablet
Pantoprazole sod dr 40 mg tablet3.93USD tablet
Pantoloc 40 mg Enteric-Coated Tablet2.28USD tablet
Apo-Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
Co Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
Mylan-Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
Novo-Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
Phl-Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
Pms-Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
Ran-Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
Ratio-Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
Sandoz Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4758579No1993-07-192010-07-19Us
CA2428870No2006-05-232021-11-17Canada
CA2092694No2005-04-052011-09-06Canada
CA2341031No2006-04-042019-08-12Canada
US5997903Yes1997-06-072017-06-07Us
US8754108Yes2002-05-172022-05-17Us
US6780881Yes2002-05-172022-05-17Us
US7351723Yes2002-05-172022-05-17Us
US7550153Yes2005-03-302025-03-30Us
US7553498Yes2005-03-302025-03-30Us
US7838027Yes2005-03-302025-03-30Us
US7544370Yes2006-12-072026-12-07Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)Because of gradual degradation of pantoprazole sodium during heating, the melting point cannot be determined.Not Available
water solubilityFreely soluble in water.Not Available
logP0.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.495 mg/mLALOGPS
logP2.11ALOGPS
logP2.18ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)9.15ChemAxon
pKa (Strongest Basic)3.55ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area86.33 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity90.05 m3·mol-1ChemAxon
Polarizability35.17 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9935
Blood Brain Barrier-0.5777
Caco-2 permeable+0.7262
P-glycoprotein substrateNon-substrate0.6127
P-glycoprotein inhibitor IInhibitor0.5587
P-glycoprotein inhibitor IINon-inhibitor0.9198
Renal organic cation transporterNon-inhibitor0.6285
CYP450 2C9 substrateNon-substrate0.84
CYP450 2D6 substrateNon-substrate0.8683
CYP450 3A4 substrateSubstrate0.7254
CYP450 1A2 substrateInhibitor0.7639
CYP450 2C9 inhibitorNon-inhibitor0.8054
CYP450 2D6 inhibitorNon-inhibitor0.7308
CYP450 2C19 inhibitorInhibitor0.7877
CYP450 3A4 inhibitorNon-inhibitor0.7258
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.903
Ames testNon AMES toxic0.5527
CarcinogenicityNon-carcinogens0.8108
BiodegradationNot ready biodegradable0.9972
Rat acute toxicity2.3466 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9228
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0090000000-fdcf6f79acd06edd5401
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0090000000-51e30cd23db38362ad60
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0090000000-f102a8245343f84e3b0d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0090000000-2e08d1a0248a26126d5e
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03fr-0940000000-25352b30e7648d902bc6
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0900000000-b7a2f038ef5f90fc95e1
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0900000000-66cb42b0034f31368f8e
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0090000000-378124c9a24c3a502e9f
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0090000000-f102a8245343f84e3b0d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0090000000-5e51997385e26e7da0c1
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03fr-0950000000-44836f641a9ead0cf572
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0900000000-4eb2af1f8bb7c0592920
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0900000000-8da503184069a7677ead
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0090000000-8b9e209f5ce292385d34
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0290000000-2953e2577582bbfe2ad8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0090000000-ce081988e6394cc11545
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0492000000-ad12657183be4d366241
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f79-0940000000-4c3f08a4a30021511475
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0920000000-f4a7f9db8c3b4fc1476d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-f665417f17af100e2cff
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-87b455243d8a69f87d9a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-1900000000-b7fa8fc340e8423574aa
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0391000000-73c186ec001abcb34f6e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f79-0940000000-ac37fdf680de7ab0411e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0920000000-aac8ca4662593728ba26
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-4a7e27a4f578c164c2b4
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-d3074931054ee514dbb8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-1900000000-30364d1aec50b4c1f89b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0090000000-421c0585dcef1856540f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udr-0950000000-507be5cae74281c438b7

Taxonomy

Description
This compound belongs to the class of organic compounds known as sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzimidazoles
Sub Class
Sulfinylbenzimidazoles
Direct Parent
Sulfinylbenzimidazoles
Alternative Parents
Alkyl aryl ethers / Pyridines and derivatives / Benzenoids / Imidazoles / Heteroaromatic compounds / Sulfoxides / Sulfinyl compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds
show 4 more
Substituents
Sulfinylbenzimidazole / Alkyl aryl ether / Pyridine / Benzenoid / Azole / Imidazole / Heteroaromatic compound / Sulfoxide / Azacycle / Sulfinyl compound
show 14 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organofluorine compound, aromatic ether, sulfoxide, pyridines, benzimidazoles (CHEBI:7915)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sodium:potassium-exchanging atpase activity
Specific Function
Catalyzes the hydrolysis of ATP coupled with the exchange of H(+) and K(+) ions across the plasma membrane. Responsible for acid production in the stomach.
Gene Name
ATP4A
Uniprot ID
P20648
Uniprot Name
Potassium-transporting ATPase alpha chain 1
Molecular Weight
114117.74 Da
References
  1. Moreira Dias L: Pantoprazole: a proton pump inhibitor. Clin Drug Investig. 2009;29 Suppl 2:3-12. doi: 10.2165/1153121-S0-000000000-00000. [PubMed:19938880]
  2. Cheer SM, Prakash A, Faulds D, Lamb HM: Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs. 2003;63(1):101-33. [PubMed:12487624]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF: Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2001 Dec;364(6):551-7. [PubMed:11770010]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Breedveld P, Zelcer N, Pluim D, Sonmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, Schellens JH: Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004 Aug 15;64(16):5804-11. [PubMed:15313923]
  2. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9. doi: 10.1111/j.1365-2125.2008.03303.x. Epub 2008 Nov 17. [PubMed:19076159]
  3. Dahan A, Amidon GL: Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7. doi: 10.1152/ajpgi.00102.2009. Epub 2009 Jun 18. [PubMed:19541926]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Oostendorp RL, van de Steeg E, van der Kruijssen CM, Beijnen JH, Kenworthy KE, Schinkel AH, Schellens JH: Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors. Drug Metab Dispos. 2009 Apr;37(4):917-23. doi: 10.1124/dmd.108.024901. Epub 2009 Jan 12. [PubMed:19139163]

Drug created on June 13, 2005 07:24 / Updated on November 23, 2017 11:07